Rhinology and Skull Base Unit, Department of Otorhinolaryngology, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia, Spain; Institut d Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Department of Otorhinolaryngology, Hospital Comarcal d’Inca, Mallorca, Spain.
Rhinology. 2020 Feb 1;58(1):51-58. doi: 10.4193/Rhin19.119.
Craniofacial hyperhidrosis (CFH) and flushing express nervous system autonomic dysfunction. Available reference treatments lack good compliance. The study objective was to investigate variations of CFH/flushing after two methods of sphenopalatine ganglion (SPG) blockade.
CFH patients (n=25) were randomized in a ratio of 1:3 in two groups; 1) endoscopic application of topical lidocaine over SPG (TL; n=7); 2) endoscopic injection of lidocaine in the SPG (IL; n=18). CFH, flushing, rhinorrhoea, nasal obstruction, and smell detection were scored by Visual Analogue Scale (VAS). Nasal endoscopy, acoustic rhinometry, mucociliary transport test, smell/taste test, Schirmer test, Short Form-12, Chronic Skin Diseases Questionnaire, and Skin Satisfaction Questionnaire were also performed at visit 0, 1, 3 and 6 months.
At baseline, groups reported similar CFH VAS (TL: 89.3 plus or minus 17.5mm; IL: 85.7 plus or minus 22.1mm) or flushing VAS (TL: 52.7 plus or minus 30mm; IL: 59 plus or minus 33.8mm). After 6 months, the least squares mean of CFH VAS in IL was -38.1 (-47.3 to -28.9) compared to TL 1.9 (-12.2 to 15.9). However, flushing VAS did not improve. Any rhinological measure nor quality of life test showed significant changes. One patient presented controlled epistaxis intraoperatively during IL.
This preliminary study shows the sphenopalatine blockade injection as a safe procedure. Patients with CFH or flushing had significant improvement after lidocaine injection which lasted 6 months. Due to the small sample and the lack of objective measures more studies are needed.
颅面多汗症(CFH)和潮红表现为自主神经系统功能障碍。现有的参考治疗方法缺乏良好的依从性。本研究的目的是探讨两种蝶腭神经节(SPG)阻断方法后 CFH/潮红的变化。
将 CFH 患者(n=25)按 1:3 的比例随机分为两组;1)SPG 表面利多卡因涂抹(TL;n=7);2)SPG 内利多卡因注射(IL;n=18)。用视觉模拟评分(VAS)对 CFH、潮红、流涕、鼻塞和嗅觉进行评分。鼻内镜、声鼻测量、黏液纤毛输送试验、嗅觉/味觉试验、泪液试验、SF-12 短表、慢性皮肤病问卷和皮肤满意度问卷也在 0、1、3 和 6 个月时进行。
基线时,两组患者 CFH VAS(TL:89.3 加减 17.5mm;IL:85.7 加减 22.1mm)或潮红 VAS(TL:52.7 加减 30mm;IL:59 加减 33.8mm)相似。6 个月后,IL 的 CFH VAS 最小二乘均值为-38.1(-47.3 至-28.9),而 TL 为 1.9(-12.2 至 15.9)。然而,潮红 VAS 没有改善。任何鼻科学措施或生活质量测试均未显示出显著变化。1 例患者在 IL 术中出现可控性鼻出血。
本初步研究表明,蝶腭神经节阻滞注射是一种安全的方法。CFH 或潮红患者在利多卡因注射后有显著改善,且持续 6 个月。由于样本量小且缺乏客观指标,需要进一步研究。